Search PubMed⌕ Search

PubMed · 11371375

[Screening: ethical principles].

Abstract

Mass cancer screening is new in France inasmuch as the country has never up to now carried out such a large-scale and wide-reaching public healthcare operation. The organisation of the screening brings up the question of where healthcare is actually heading. Should the community as a whole should have preference over the individual or, on the other hand, should the individual and his or her private life be defended against a faceless community that is becoming more and more demanding? This question is fundamental to all the difficulties that are met when organising mass screenings. There are, of course, certain technical aspects and indicators of effectiveness that are common to all screening campaigns, but there are also wider considerations that must be respected, such as social justice and liberty of both the individual and the community. Anyone who wishes to take advantage of the screening should be free to do so, but the individual must also be free to refuse. Screening must remain voluntary. It is essential to maintain full data secrecy and to provide appropriate training for the doctors involved. It is also of fundamental importance to carry out an assessment of the campaign from a neutral angle. The training issue is crucial, with the doctor's suitability to carry out the test a key factor. Doctors need to be trained to acquire the necessary skills, especially as it will soon become necessary to monitor doctors' competence in the field. An assessment will have to be made not simply of performance but also of doctors' ability to handle a given situation.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

P Haehnel. 2001. [Screening: ethical principles].. https://pubmed.ncbi.nlm.nih.gov/11371375/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Food labeling: trans fatty acids in nutrition labeling, nutrient content claims, and health claims. Final rule.

The Food and Drug Administration (FDA) is amending its regulations on nutrition labeling to require that trans fatty acids be declared in the nutrition label of conventional foods and dietary supplements on a separate line immediately under the line for the declaration of saturated fatty acids. This action responds, in part, to a citizen petition from the Center for Science in the Public Interest (CSPI). This rule is intended to provide information to assist consumers in maintaining healthy dietary practices. Those sections of the proposed rule pertaining to the definition of nutrient content claims for the "free" level of trans fatty acids and to limits on the amounts of trans fatty acids wherever saturated fatty acid limits are placed on nutrient content claims, health claims, and disclosure and disqualifying levels are being withdrawn. Further, the agency is withdrawing the proposed requirement to include a footnote stating: "Intake of trans fat should be as low as possible." Issues related to the possible use of a footnote statement in conjunction with the trans fat label declaration or in the context of certain nutrient content and health claims that contain messages about cholesterol-raising fats in the diet are now the subject of an advance notice of proposed rulemaking (ANPRM) which is published elsewhere in this issue of the Federal Register.

Community Participation↗